Stagezero Life Sciences Stock Performance
| SZLSF Stock | USD 0.0005 0.00 0.00% |
The entity has a beta of 1.53, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, StageZero Life will likely underperform. At this point, StageZero Life Sciences has a negative expected return of -1.39%. Please make sure to validate StageZero Life's mean deviation, treynor ratio, as well as the relationship between the Treynor Ratio and day median price , to decide if StageZero Life Sciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days StageZero Life Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 6.6 M | |
| Total Cashflows From Investing Activities | -21 K | |
| Free Cash Flow | -9.1 M |
StageZero |
StageZero Life Relative Risk vs. Return Landscape
If you would invest 0.51 in StageZero Life Sciences on November 10, 2025 and sell it today you would lose (0.46) from holding StageZero Life Sciences or give up 90.2% of portfolio value over 90 days. StageZero Life Sciences is currently producing negative expected returns and takes up 11.1874% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than StageZero, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
StageZero Life Target Price Odds to finish over Current Price
The tendency of StageZero Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.0005 | 90 days | 0.0005 | about 81.75 |
Based on a normal probability distribution, the odds of StageZero Life to move above the current price in 90 days from now is about 81.75 (This StageZero Life Sciences probability density function shows the probability of StageZero Pink Sheet to fall within a particular range of prices over 90 days) .
StageZero Life Price Density |
| Price |
Predictive Modules for StageZero Life
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as StageZero Life Sciences. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of StageZero Life's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
StageZero Life Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. StageZero Life is not an exception. The market had few large corrections towards the StageZero Life's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold StageZero Life Sciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of StageZero Life within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.5 | |
β | Beta against Dow Jones | 1.53 | |
σ | Overall volatility | 0 | |
Ir | Information ratio | -0.13 |
StageZero Life Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of StageZero Life for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for StageZero Life Sciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| StageZero Life generated a negative expected return over the last 90 days | |
| StageZero Life has high historical volatility and very poor performance | |
| StageZero Life has some characteristics of a very speculative penny stock | |
| StageZero Life Sciences has accumulated 582.46 K in total debt with debt to equity ratio (D/E) of 0.95, which is about average as compared to similar companies. StageZero Life Sciences has a current ratio of 0.13, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist StageZero Life until it has trouble settling it off, either with new capital or with free cash flow. So, StageZero Life's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like StageZero Life Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for StageZero to invest in growth at high rates of return. When we think about StageZero Life's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 5.07 M. Net Loss for the year was (7.48 M) with profit before overhead, payroll, taxes, and interest of 1.18 M. | |
| StageZero Life Sciences has accumulated about 90.63 K in cash with (8.95 M) of positive cash flow from operations. |
StageZero Life Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of StageZero Pink Sheet often depends not only on the future outlook of the current and potential StageZero Life's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. StageZero Life's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 90.7 M | |
| Short Long Term Debt | 358.4 K | |
| Shares Float | 87.4 M |
StageZero Life Fundamentals Growth
StageZero Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of StageZero Life, and StageZero Life fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on StageZero Pink Sheet performance.
| Return On Equity | -1.69 | |||
| Return On Asset | -0.61 | |||
| Profit Margin | (0.91) % | |||
| Operating Margin | (1.99) % | |||
| Current Valuation | 6.93 M | |||
| Shares Outstanding | 101.53 M | |||
| Price To Book | 4.22 X | |||
| Price To Sales | 1.17 X | |||
| Revenue | 5.07 M | |||
| EBITDA | (6.77 M) | |||
| Cash And Equivalents | 90.63 K | |||
| Total Debt | 582.46 K | |||
| Debt To Equity | 0.95 % | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (8.95 M) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 10.65 M | |||
About StageZero Life Performance
By analyzing StageZero Life's fundamental ratios, stakeholders can gain valuable insights into StageZero Life's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if StageZero Life has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if StageZero Life has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. The company was founded in 1998 and is headquartered in Richmond Hill, Canada. Stagezero Life operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 80 people.Things to note about StageZero Life Sciences performance evaluation
Checking the ongoing alerts about StageZero Life for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for StageZero Life Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| StageZero Life generated a negative expected return over the last 90 days | |
| StageZero Life has high historical volatility and very poor performance | |
| StageZero Life has some characteristics of a very speculative penny stock | |
| StageZero Life Sciences has accumulated 582.46 K in total debt with debt to equity ratio (D/E) of 0.95, which is about average as compared to similar companies. StageZero Life Sciences has a current ratio of 0.13, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist StageZero Life until it has trouble settling it off, either with new capital or with free cash flow. So, StageZero Life's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like StageZero Life Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for StageZero to invest in growth at high rates of return. When we think about StageZero Life's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 5.07 M. Net Loss for the year was (7.48 M) with profit before overhead, payroll, taxes, and interest of 1.18 M. | |
| StageZero Life Sciences has accumulated about 90.63 K in cash with (8.95 M) of positive cash flow from operations. |
- Analyzing StageZero Life's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether StageZero Life's stock is overvalued or undervalued compared to its peers.
- Examining StageZero Life's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating StageZero Life's management team can have a significant impact on its success or failure. Reviewing the track record and experience of StageZero Life's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of StageZero Life's pink sheet. These opinions can provide insight into StageZero Life's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for StageZero Pink Sheet analysis
When running StageZero Life's price analysis, check to measure StageZero Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy StageZero Life is operating at the current time. Most of StageZero Life's value examination focuses on studying past and present price action to predict the probability of StageZero Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move StageZero Life's price. Additionally, you may evaluate how the addition of StageZero Life to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |